Panoraia I. Siafaka

Dr. Panoraia I. Siafaka

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Chemical Engineering Journal
Verified
Journal Article
Closed access
George Z. KyzasGeorge Z. Kyzas
George Z. Kyzas
Panoraia I. SiafakaPanoraia I. Siafaka
Panoraia I. Siafaka
EPEleni G. Pavlidou
Eleni G. Pavlidou
KCKonstantinos Chrissafis
Konstantinos Chrissafis
Dimitrios BikiarisDimitrios Bikiaris
Dimitrios Bikiaris

1 November 2020 in Asian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
MOMehmet Evren Okur
Mehmet Evren Okur
IKIoannis Karantas
Ioannis Karantas
ZŞZeynep Şenyiğit
Zeynep Şenyiğit
Neslihan Üstündağ OkurNeslihan Üstündağ Okur
Neslihan Üstündağ Okur
Panoraia I. SiafakaPanoraia I. Siafaka
Panoraia I. Siafaka
Wound healing is an unmet therapeutic challenge among medical society since wound assessment and management is a complex procedure including several factors playing major role in healing process. Wounds can mainly be categorized as acute or chronic. It is well referred that the acute wound displays normal wound physiology while healing, in most cases, is seemed to progress through the normal phases of wound healing. On the other hand, a chronic wound is physiologically impaired. The main problem in wound management is that the majority of wounds are colonized with microbes, whereas this does not mean that all wounds will be infected. In this review, we address the problems that clinicians face to manage while treat acute and chronic wounds. Moreover, we demonstrate the pathophysiology, etiology, prognosis and microbiology of wounds. We further introduce the state of art in pharmaceutical technology field as part of wound management aiming to assist health professionals to overcome the current implications on wound assessment. In addition, authors review researches which included the use of gels and dermal films as wound healing agents. It can be said that natural and synthetic drugs or carriers provide promising solutions in order to meet the wound management standards. However, are the current strategies as desirable as medical society wish?

Verified
Journal Article
Open access
PDF file
Panoraia I. SiafakaPanoraia I. Siafaka
Panoraia I. Siafaka
Neslihan Üstündağ OkurNeslihan Üstündağ Okur
Neslihan Üstündağ Okur
EKEvangelos Karavas
Evangelos Karavas
Dimitrios BikiarisDimitrios Bikiaris
Dimitrios Bikiaris
Nanocarriers, due to their unique features, are of increased interest among researchers working with pharmaceutical formulations. Polymeric nanoparticles and nanocapsules, involving non-toxic biodegradable polymers, liposomes, solid lipid nanoparticles, and inorganic–organic nanomaterials, are among the most used carriers for drugs for a broad spectrum of targeted diseases. In fact, oral, injectable, transdermal-dermal and ocular formulations mainly consist of the aforementioned nanomaterials demonstrating promising characteristics such as long circulation, specific targeting, high drug loading capacity, enhanced intracellular penetration, and so on. Over the last decade, huge advances in the development of novel, safer and less toxic nanocarriers with amended properties have been made. In addition, multifunctional nanocarriers combining chemical substances, vitamins and peptides via coupling chemistry, inorganic particles coated by biocompatible materials seem to play a key role considering that functionalization can enhance characteristics such as biocompatibility, targetability, environmental friendliness, and intracellular penetration while also have limited side effects. This review aims to summarize the “state of the art” of drug delivery carriers in nanosize, paying attention to their surface functionalization with ligands and other small or polymeric compounds so as to upgrade active and passive targeting, different release patterns as well as cell targeting and stimuli responsibility. Lastly, future aspects and potential uses of nanoparticulated drug systems are outlined.

3 January 2014 in Langmuir
Verified
Journal Article
Closed access
George Z. KyzasGeorge Z. Kyzas
George Z. Kyzas
Panoraia I. SiafakaPanoraia I. Siafaka
Panoraia I. Siafaka
DLDIMITRA LAMBROPOULOU
DIMITRA LAMBROPOULOU
NLNikolaos K. Lazaridis
Nikolaos K. Lazaridis
Dimitrios BikiarisDimitrios Bikiaris
Dimitrios Bikiaris

1 June 2016 in Carbohydrate Polymers
Verified
Journal Article
Closed access
Panoraia I. SiafakaPanoraia I. Siafaka
Panoraia I. Siafaka
AZAsimina Zisi
Asimina Zisi
MEMaria K. Exindari
Maria K. Exindari
IKIoannis Karantas
Ioannis Karantas
Dimitrios BikiarisDimitrios Bikiaris
Dimitrios Bikiaris

1 July 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MFMaria Filippousi
Maria Filippousi
STStuart Turner
Stuart Turner
Karen LeusKaren Leus
Karen Leus
Panoraia I. SiafakaPanoraia I. Siafaka
Panoraia I. Siafaka
ETEirini D. Tseligka
Eirini D. Tseligka
GTGustaaf Van Tendeloo
Gustaaf Van Tendeloo